Nobel Prize for Medicine goes to optogenetics architects

The Nobel Prize in Physiology or Medicine 2026 has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel for their development of optogenetics technology, in which the activity of neurons can be characterized and manipulated with light, effectively switching them on or off.

"Optogenetics has fundamentally altered our understanding of the brain," noted the Nobel Committee in its citation. "Every day brings new discoveries, helping to solve one of humanity's great mysteries: how our incredible brain works."

The roots of this impact go back four decades to Hegemann's studies of light-responsive green algae, and subsequent work alongside Nagel showing that a single gene in an algae was capable of producing large photocurrents when expressed.

Stanford's Deisseroth started work on the topic in 2004, developing a process to insert light-sensitive microbial proteins called opsins into mammalian brain cells and so allowing them to undergo optogenetic control. His team achieved the first single-cell-resolution optogenetic control of neuronal activity and behavior in living mammals.

"I couldn’t be happier because the trio that the committee picked spans the progression from the early algal explorations all the way to advanced neuroscience experiments," commented Deisseroth. "So this prize really captures the full journey of discovery."

Instruments in the optogenetic orchestra

In previous years optogenetics has been recognized by other awards committees, with its pioneers receiving the Brain Prize in 2013 and the celebrity-sprinkled Breakthrough Prize in Life Sciences in 2015. In 2019 Deisseroth and Hegemann, alongside colleagues Ed Boyden and Gero Miesenböck, won the Warren Alpert Foundation Prize for medical research, an award sometimes framed as a precursor to Nobel Prize success - a framing that has now duly become reality.

Continuing developments in optogenetics have seen the technique refined to study the mechanisms of epilepsy and to indicate possible routes to future treatment for the condition. This involves using light to control seizure activity in living human brain tissue, an environment where achieving the expression of light-sensitive proteins needed for optogenetics to work has proven difficult. 

Optogenetics has also been applied outside the brain as a potential way to stimulate muscle activity in patients experiencing paralysis, potentially "a minimally invasive strategy that would change the game in terms of clinical care," according to the MIT researchers behind the study. 

The variety of potential applications reflects the flexibility of the technique, and the way that neuroscientists can use different optical parameters to manipulate cell behavior without direct genetic engineering. Deisseroth has likened the range of recent advances to addition of instruments in an "optogenetic orchestra."

"Optogenetics is much more than a technical breakthrough," wrote the Nobel Assembly. "The method has transformed neuroscience from observing and 'reading' brain activity to actively 'writing' into it, establishing a causal link between distributed, genetically specialized circuit motifs and behavior, emotion and cognition."